These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15887013)

  • 1. Chaperone-rich cell lysates, immune activation and tumor vaccination.
    Zeng Y; Graner MW; Katsanis E
    Cancer Immunol Immunother; 2006 Mar; 55(3):329-38. PubMed ID: 15887013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
    Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
    Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity.
    Zeng Y; Feng H; Graner MW; Katsanis E
    Blood; 2003 Jun; 101(11):4485-91. PubMed ID: 12576309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
    Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
    Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
    Kislin KL; Marron MT; Li G; Graner MW; Katsanis E
    FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.
    Graner MW; Zeng Y; Feng H; Katsanis E
    Cancer Immunol Immunother; 2003 Apr; 52(4):226-34. PubMed ID: 12669247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity.
    Graner MW; Romanoski A; Katsanis E
    Int J Hyperthermia; 2013 Aug; 29(5):380-9. PubMed ID: 23725202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
    Koide T; Iinuma H; Fukushima R
    Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
    Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
    J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.
    Li G; Zeng Y; Chen X; Larmonier N; Sepassi M; Graner MW; Andreansky S; Brewer MA; Katsanis E
    Clin Exp Immunol; 2007 Apr; 148(1):136-45. PubMed ID: 17349014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure.
    Mayer-Sonnenfeld T; Har-Noy M; Lillehei KO; Graner MW
    Int J Hyperthermia; 2013 Sep; 29(6):520-7. PubMed ID: 23734882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity.
    Feng H; Zeng Y; Graner MW; Likhacheva A; Katsanis E
    Blood; 2003 Jan; 101(1):245-52. PubMed ID: 12393411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.
    Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H
    Med Oncol; 2006; 23(2):273-82. PubMed ID: 16720928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.
    Cantrell J; Larmonier C; Janikashvili N; Bustamante S; Fraszczak J; Herrell A; Lundeen T; J LaCasse C; Situ E; Larmonier N; Katsanis E
    Immunobiology; 2010 Jul; 215(7):535-44. PubMed ID: 19880213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in dendritic cell-based vaccine of cancer.
    Zhang X; Gordon JR; Xiang J
    Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.